| Year |
Title |
Altmetric |
| 2020
|
STAT3 and GR cooperate to drive gene expression and growth of basal-like triple-negative breast cancer..
Cancer Research.
2020
|
|
| 2020
|
PDE5 and PDE10 inhibition activates cGMP/PKG signaling to block Wnt/β-catenin transcription, cancer cell growth, and tumor immunity.
Drug Discovery Today.
25:1521-1527.
2020
|
|
| 2020
|
PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its Progression.
Translational Oncology.
13.
2020
|
|
| 2020
|
B7-H3-targeted radioimmunotherapy of human cancer.
Current Medicinal Chemistry.
27:4016-4038.
2020
|
|
| 2020
|
Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer
2020
|
|
| 2019
|
Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1
2019
|
|
| 2019
|
The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth
2019
|
|
| 2018
|
The antitumor effects of entinostat in ovarian cancer require adaptive immunity.
Cancer.
124:4657-4666.
2018
|
|
| 2018
|
Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells.
Journal of Cellular Biochemistry.
119:6216-6230.
2018
|
|
| 2018
|
Corrigendum to ‘212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models’ [Nucl Med Biol 58 (2018) 67–73] (S0969805117303396) (10.1016/j.nucmedbio.2017.12.004)).
Nuclear Medicine and Biology.
61:71.
2018
|
|
| 2018
|
Retraction notice to “SRI36160 is a specific inhibitor of Wnt/<beta>-catenin signaling in human pancreatic and colorectal cancer cells” [Canc. Lett. 389C (2017) 41–48] (S030438351630800X) (10.1016/j.canlet.2016.12.030)).
Cancer Letters.
422:131.
2018
|
|
| 2018
|
Preferential inhibition of Wnt/β-catenin signaling by novel benzimidazole compounds in triple-negative breast cancer.
International Journal of Molecular Sciences.
19.
2018
|
|
| 2018
|
Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer [Oncotarget., 7, (2016) (86803-86815)] 10.18632/oncotarget.13466.
Oncotarget.
9:19459-19459.
2018
|
|
| 2018
|
212Pb-labeled antibody 225.28 targeted to chondroitin sulfate proteoglycan 4 for triple-negative breast cancer therapy in mouse models.
International Journal of Molecular Sciences.
19.
2018
|
|
| 2018
|
212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models.
Nuclear Medicine and Biology.
58:67-73.
2018
|
|
| 2018
|
CD38 pretargeted RIT of B-cell tumors.
Blood.
131:589-590.
2018
|
|
| 2018
|
ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage.
Journal of Biological Chemistry.
293:984-994.
2018
|
|
| 2017
|
Modulation of antitumor immunity with histone deacetylase inhibitors.
Immunotherapy.
9:1359-1372.
2017
|
|
| 2017
|
Survivin a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs..
Clinical and Translational Medicine.
6:11.
2017
|
|
| 2017
|
Retraction of "Design and Synthesis of Novel Cyclic Amine Benzimidazoles for the Treatment of Pancreatic Cancer"..
Journal of Medicinal Chemistry.
60:7615.
2017
|
|
| 2017
|
Calmodulin Binding to Death Receptor 5-mediated Death-Inducing Signaling Complex in Breast Cancer Cells.
Journal of Cellular Biochemistry.
118:2285-2294.
2017
|
|
| 2017
|
Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review.
Gynecologic Oncology Reports.
20:81-86.
2017
|
|
| 2017
|
B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models.
Nuclear Medicine and Biology.
47:23-30.
2017
|
|
| 2017
|
SRI36160 is a specific inhibitor of Wnt/β-catenin signaling in human pancreatic and colorectal cancer cells.
Cancer Letters.
389:41-48.
2017
|
|
| 2017
|
Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.
Oncotarget.
8:44159-44170.
2017
|
|
| 2017
|
Genomic regulation of invasion by STAT3 in triple negative breast cancer.
Oncotarget.
8:8226-8238.
2017
|
|
| 2017
|
Journey of TRAIL from bench to bedside and its potential role in immuno-oncology.
Oncology Reviews.
11:26-42.
2017
|
|
| 2016
|
RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4.
Molecular Oncology.
10:1169-1182.
2016
|
|
| 2016
|
Ovarian cancer and the immune system — The role of targeted therapies.
Gynecologic Oncology.
142:349-356.
2016
|
|
| 2016
|
Role of nanotechnology and gene delivery systems in TRAIL-based therapies.
Ecancermedicalscience.
10.
2016
|
|
| 2016
|
The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotype.
Cancer Research.
76:3978-3988.
2016
|
|
| 2016
|
Characterization of the interactions between calmodulin and death receptor 5 in triple-negative and estrogen receptor-positive breast cancer cells: An integrated experimental and computational study.
Journal of Biological Chemistry.
291:12862-12870.
2016
|
|
| 2016
|
A Novel Imaging Biomarker Extracted from Fluorescence Microscopic Imaging of TRA-8/DR5 Oligomers Predicts TRA-8 Therapeutic Efficacy in Breast and Pancreatic Cancer Mouse Models
2016
|
|
| 2016
|
Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes..
Cancer Immunology Research.
4:390-399.
2016
|
|
| 2016
|
SPARC-independent delivery of nab-paclitaxel without depleting tumor stroma in patient-derived pancreatic Cancer xenografts.
Molecular Cancer Therapeutics.
15:680-688.
2016
|
|
| 2016
|
Surveying the serologic proteome in a tissue-specific kras(G12D) knockin mouse model of pancreatic cancer.
Proteomics.
16:516-531.
2016
|
|
| 2016
|
Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974.
Laboratory Investigation.
96:249-259.
2016
|
|
| 2016
|
Loss of tumor suppressor Merlin results in aberrant activation of Wnt/β-catenin signaling in cancer.
Oncotarget.
7:17991-18005.
2016
|
|
| 2016
|
Niclosamide and its analogs are potent inhibitors of Wnt/ß- catenin, mTOR and STAT3 signaling in ovarian cancer.
Oncotarget.
7:86803-86815.
2016
|
|
| 2015
|
Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer.
Journal of the Egyptian National Cancer Institute.
27:205-215.
2015
|
|
| 2015
|
Dynamic contrast enhanced magnetic resonance imaging of an orthotopic pancreatic cancer mouse model.
Journal of Visualized Experiments.
2015.
2015
|
|
| 2015
|
S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase.
Scientific Reports.
5.
2015
|
|
| 2015
|
Dynamic contrast enhanced magnetic resonance imaging of an orthotopic pancreatic cancer mouse model.
Journal of Visualized Experiments.
2015
|
|
| 2015
|
Niclosamide analogs for treatment of ovarian cancer.
International Journal of Gynecological Cancer.
25:1377-1385.
2015
|
|
| 2015
|
Ovarian and cervical cancer patient derived xenografts: The past, present, and future.
Gynecologic Oncology.
138:486-491.
2015
|
|
| 2014
|
Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?.
World Journal of Stem Cells.
6:441-447.
2014
|
|
| 2014
|
Pazopanib combined with radiation: In vivo model of interaction.
Cancer Biotherapy and Radiopharmaceuticals.
29:247-250.
2014
|
|
| 2014
|
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.
Cancer Letters.
349:8-14.
2014
|
|
| 2014
|
Loss of N-Myc interactor promotes epithelial-mesenchymal transition by activation of TGF-β/SMAD signaling.
Oncogene.
33:2620-2628.
2014
|
|
| 2014
|
Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers
2014
|
|
| 2014
|
Will detection of microRNA biomarkers in blood improve the diagnosis and survival of patients with pancreatic cancer?
2014
|
|
| 2014
|
Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer.
Cancer Biology and Therapy.
15:1053-1060.
2014
|
|
| 2014
|
Effect of niclosamide on basal-like breast cancers.
Molecular Cancer Therapeutics.
13:800-811.
2014
|
|
| 2014
|
Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus.
Cancer Gene Therapy.
21:264-274.
2014
|
|
| 2014
|
Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer.
Gynecologic Oncology.
134:112-120.
2014
|
|
| 2014
|
MicroRNA results may differ with age.
Oncology Report.
4.
2014
|
|
| 2014
|
Monoclonal antibody-based immunotherapy of ovarian cancer: Targeting ovarian cancer cells with the B7-H3-specific mAb 376.96.
Gynecologic Oncology.
132:203-210.
2014
|
|
| 2014
|
Recurrent read-through fusion transcripts in breast cancer.
Breast Cancer Research and Treatment.
146:287-297.
2014
|
|
| 2013
|
The Wnt/β-catenin pathway in ovarian cancer: A review.
Gynecologic Oncology.
131:772-779.
2013
|
|
| 2013
|
Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.
Molecular Cancer Therapeutics.
12:2110-2120.
2013
|
|
| 2013
|
Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.
Annals of Surgical Oncology.
20:3059-3065.
2013
|
|
| 2013
|
ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines.
Cancer Research.
73:2368-2378.
2013
|
|
| 2013
|
The C-Terminal Region Mesd Peptide Mimics Full-Length Mesd and Acts as an Inhibitor of Wnt/β-Catenin Signaling in Cancer Cells.
PLoS ONE.
8.
2013
|
|
| 2013
|
KM method in estimation of Tumor Doubling time in Animal experiment.
Journal of the American Statistical Association, Section on Nonparametric Statistics.
2013:3611-3615.
2013
|
|
| 2012
|
A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer.
Gynecologic Oncology.
127:420-425.
2012
|
|
| 2012
|
A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model.
Pancreas.
41:789-796.
2012
|
|
| 2012
|
Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity.
Breast Cancer Research and Treatment.
133:437-445.
2012
|
|
| 2012
|
Effect of anti-DR5 and chemotherapy on basal-like breast cancer.
Breast Cancer Research and Treatment.
133:417-426.
2012
|
|
| 2012
|
The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells.
Gynecologic Oncology.
125:226-230.
2012
|
|
| 2012
|
Progress in cancer therapy.
Cancer Biotherapy and Radiopharmaceuticals.
27:1.
2012
|
|
| 2012
|
The use of retinoids in ovarian cancer: A review of the literature.
International Journal of Gynecological Cancer.
22:191-198.
2012
|
|
| 2012
|
Cancer Treatment with Gene Therapy and Radiation Therapy.
Advances in Cancer Research.
115:221-263.
2012
|
|
| 2011
|
Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiation.
Radiotherapy and Oncology.
101:183-189.
2011
|
|
| 2011
|
Cellular model of Warburg Effect identifies tumor promoting function of UCP2 in breast cancer and its suppression by genipin.
PLoS ONE.
6.
2011
|
|
| 2011
|
Relationship between galectin-3 expression and TRAIL sensitivity in breast cancer
2011
|
|
| 2011
|
Molecular targeted approaches for treatment of pancreatic cancer.
Current Pharmaceutical Design.
17:2221-2238.
2011
|
|
| 2011
|
Thrombospondin-1 opens the paracellular pathway in pulmonary microvascular endothelia through EGFR/ErbB2 activation
2011
|
|
| 2011
|
Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging.
Molecular Imaging.
10:153-167.
2011
|
|
| 2011
|
A phase i study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer.
Cancer Chemotherapy and Pharmacology.
67:891-897.
2011
|
|
| 2011
|
Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.
Gynecologic Oncology.
121:193-199.
2011
|
|
| 2011
|
Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells
2011
|
|
| 2011
|
Combined modality therapy with TRAIL or agonistic death receptor antibodies.
Cancer Biology and Therapy.
11:431-449.
2011
|
|
| 2011
|
DCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 Therapy
2011
|
|
| 2011
|
Evaluation of the Effectiveness of Two Drugs Combination Therapy in Vitro Cytotoxicity Study.
Journal of the American Statistical Association, Section on Statistical Consulting.
2011:5147-5152.
2011
|
|
| 2010
|
KISS1 over-expression suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse model.
Clinical and Experimental Metastasis.
27:591-600.
2010
|
|
| 2010
|
Overcoming TRAIL resistance in ovarian carcinoma.
Gynecologic Oncology.
119:157-163.
2010
|
|
| 2010
|
A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer.
Pancreas.
39:913-922.
2010
|
|
| 2009
|
Monoclonal antibodies in the treatment of pancreatic cancer.
Immunotherapy.
1:223-239.
2009
|
|
| 2009
|
Experimental cancer therapy using restoration of NAD+-linked 15-hydroxyprostaglandin dehydrogenase expression.
Molecular Cancer Therapeutics.
8:3130-3139.
2009
|
|
| 2009
|
CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma.
Cancer Gene Therapy.
16:794-805.
2009
|
|
| 2009
|
Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model.
International Journal of Gynecological Cancer.
19:814-819.
2009
|
|
| 2009
|
Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1.
Molecular Pharmacology.
76:81-90.
2009
|
|
| 2009
|
Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: A mechanism for immune evasion in cancer.
Journal of Immunology.
182:7548-7557.
2009
|
|
| 2009
|
Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer.
Clinical Cancer Research.
15:4058-4065.
2009
|
|
| 2009
|
Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer.
Gynecologic Oncology.
113:384-390.
2009
|
|
| 2009
|
Therapy of head and neck squamous cell carcinoma with replicative adenovirus expressing tissue inhibitor of metalloproteinase-2 and chemoradiation.
Cancer Gene Therapy.
16:246-255.
2009
|
|
| 2008
|
In vivo efficacy of marimastat and chemoradiation in head and neck cancer xenografts.
ORL.
71:1-5.
2008
|
|
| 2008
|
In Reply to Dr. Speer
2008
|
|
| 2008
|
Immunohistochemistry in the evaluation of neovascularization in tumor xenografts
2008
|
|
| 2008
|
Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene.
Molecular Cancer Therapeutics.
7:2845-2854.
2008
|
|
| 2008
|
Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenograftsby diffusion-weighted magnetic resonance imaging.
Cancer Research.
68:8369-8376.
2008
|
|
| 2008
|
Molecular targeted therapies for pancreatic cancer
2008
|
|
| 2008
|
Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects.
Vaccine.
26:4314-4319.
2008
|
|
| 2008
|
Enhancement of Glioma Radiotherapy and Chemotherapy Response With Targeted Antibody Therapy Against Death Receptor 5
2008
|
|
| 2008
|
Effect of TRA-8 anti-DR5 monoclonal antibody in combination with chemotherapy in an ex vivo human ovarian cancer model..
Journal of Clinical Oncology.
26:14695.
2008
|
|
| 2008
|
Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model.
Gut.
57:634-641.
2008
|
|
| 2008
|
Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
Clinical Cancer Research.
14:2180-2189.
2008
|
|
| 2008
|
Erratum: Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma (Gene Therapy (2008) vol. 14 (1111-1119) 10.1038/sj.gt.3302965)
2008
|
|
| 2008
|
Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model.
Gynecologic Oncology.
108:591-597.
2008
|
|
| 2007
|
TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth.
Molecular Cancer Therapeutics.
6:3198-3207.
2007
|
|
| 2007
|
EGFR Genomic Gain and Aberrant Pathway Signaling in Pancreatic Cancer Patients.
Journal of Surgical Research.
143:20-26.
2007
|
|
| 2007
|
Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer.
Clinical Cancer Research.
13.
2007
|
|
| 2007
|
Combination treatment with TRA-8 anti-death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer.
Clinical Cancer Research.
13.
2007
|
|
| 2007
|
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers.
Gynecologic Oncology.
106:614-621.
2007
|
|
| 2007
|
TRAIL-receptor antibodies as a potential cancer treatment.
Future Oncology.
3:405-409.
2007
|
|
| 2007
|
Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response.
Annals of Surgical Oncology.
14:2150-2158.
2007
|
|
| 2007
|
Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model.
Gynecologic Oncology.
105:291-298.
2007
|
|
| 2007
|
Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer.
Surgery.
141:464-469.
2007
|
|
| 2007
|
High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m-labeled anti-DR5 antibody in breast tumor xenografts.
Molecular Cancer Therapeutics.
6:866-875.
2007
|
|
| 2007
|
ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.
Cancer Biology and Therapy.
6:548-554.
2007
|
|
| 2007
|
Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma
2007
|
|
| 2007
|
Single-photon emission computed tomography imaging with a humanized, apoptosis-inducing antibody targeting human death receptor 5 in pancreas and breast tumor xenografts.
Cancer Biology and Therapy.
6:1392-1398.
2007
|
|
| 2006
|
Oncolytic HSV-1 for the treatment of brain tumours
2006
|
|
| 2006
|
Treatment With Gemcitabine and TRA-8 Anti-Death Receptor-5 mAb Reduces Pancreatic Adenocarcinoma Cell Viability In Vitro and Growth In Vivo.
Journal of Gastrointestinal Surgery.
10:1291-1300.
2006
|
|
| 2006
|
Pretargeted radioimmunotherapy
2006
|
|
| 2006
|
Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function.
Cancer Research.
66:8520-8528.
2006
|
|
| 2006
|
TRAIL receptor-targeted therapy.
Future Oncology.
2:493-508.
2006
|
|
| 2006
|
Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
Gynecologic Oncology.
101:46-54.
2006
|
|
| 2006
|
Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity.
Cancer Gene Therapy.
13:203-214.
2006
|
|
| 2006
|
Gene delivery and gene therapy of prostate cancer.
Expert Opinion on Drug Delivery.
3:37-51.
2006
|
|
| 2006
|
Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array. Application to Hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma
2006
|
|
| 2005
|
Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: Clinical implications of abscopal effects.
Clinical Cancer Research.
11:8773-8781.
2005
|
|
| 2005
|
Erratum: Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region (Cancer Biotherapy and Radiopharmaceuticals (2005) 20, 5 (502-513)).
Cancer Biotherapy and Radiopharmaceuticals.
20:671.
2005
|
|
| 2005
|
Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.
Cancer Biotherapy and Radiopharmaceuticals.
20:502-513.
2005
|
|
| 2005
|
Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
Clinical Cancer Research.
11:8180-8185.
2005
|
|
| 2005
|
TRAIL death receptor therapy for malignant glioma..
Journal of Clinical Oncology.
23:3187.
2005
|
|
| 2005
|
TRAIL-mediated induction of apoptosis as a targeted therapy for prostate cancer..
Journal of Clinical Oncology.
23:3186.
2005
|
|
| 2005
|
The small heat shock protein αB-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3.
Journal of Biological Chemistry.
280:11059-11066.
2005
|
|
| 2005
|
Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas
2005
|
|
| 2005
|
Development and analyses of CPT-11 resistant sublines of human colorectal adenocarcinoma cell line, SW-948.
Proceedings of the American Association of Cancer Research.
46:350-350.
2005
|
|
| 2005
|
Radiotargeted gene therapy.
Journal of Nuclear Medicine.
46.
2005
|
|
| 2004
|
Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer.
Molecular Therapy.
10:1059-1070.
2004
|
|
| 2004
|
Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells.
Journal of Gastrointestinal Surgery.
8:960-970.
2004
|
|
| 2004
|
Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.
Bioconjugate Chemistry.
15:1264-1274.
2004
|
|
| 2004
|
Detection of disseminated breast cancer growth and treatment response using non-invasive bioluminescence imaging..
Journal of Clinical Oncology.
22:742.
2004
|
|
| 2004
|
Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells
2004
|
|
| 2004
|
Adenoviral vector-mediated augmentation of epidermal growth factor receptor (EGFr) enhances the radiosensitization properties of anti-EGFr treatment in prostate cancer cells
2004
|
|
| 2004
|
Anti-EGFR-mediated radiosensitization as a result of augmented EGFR expression
2004
|
|
| 2004
|
Gene expression imaging with radiolabeled peptides.
Annals of Nuclear Medicine.
18:275-283.
2004
|
|
| 2004
|
Imaging and Therapy of Tumors Induced to Express Somatostatin Receptor by Gene Transfer Using Radiolabeled Peptides and Single Chain Antibody Constructs.
Seminars in Nuclear Medicine.
34:32-46.
2004
|
|
| 2003
|
Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.
Clinical Cancer Research.
9:3731-3741.
2003
|
|
| 2003
|
Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model..
Clinical Cancer Research.
9:3731-3741.
2003
|
|
| 2003
|
Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody.
Journal of Surgical Research.
111:274-283.
2003
|
|
| 2003
|
Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway.
Oncogene.
22:2034-2044.
2003
|
|
| 2003
|
An adenovirus encoding proapoptotic Bax synergistically radiosensitizes malignant glioma
2003
|
|
| 2003
|
Invited commentary: targeting of 125I-labeled B lymphocyte stimulator..
Journal of Nuclear Medicine.
44:434-436.
2003
|
|
| 2003
|
Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.
Bioconjugate Chemistry.
14:302-310.
2003
|
|
| 2003
|
Targeting of 125I-labeled B lymphocyte stimulator.
Journal of Nuclear Medicine.
44:434-436.
2003
|
|
| 2003
|
Three-dimensional dose model for the comparison of 177Lu-HuCC49ΔCH2 and 177Lu-HuCC49 radioimmunotherapy in mice bearing intraperitoneal xenografts.
Cancer Biotherapy and Radiopharmaceuticals.
18:239-247.
2003
|
|
| 2002
|
Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation
2002
|
|
| 2002
|
Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: Implications for a dual modality treatment using capecitabine and irradiation.
Molecular Cancer Therapeutics.
1:1139-1145.
2002
|
|
| 2002
|
Adenovirus-mediated transfer of BAX driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells.
Molecular Therapy.
6:190-198.
2002
|
|
| 2002
|
De novo synthesis of a new diethylenetriaminepentaacetic acid (DTPA) bifunctional chelating agent.
Bioconjugate Chemistry.
13:317-326.
2002
|
|
| 2002
|
Synthesis of the first diethylenetriaminepentahydroxamic acid (DTPH) bifunctional chelating agent.
Bioconjugate Chemistry.
13:327-332.
2002
|
|
| 2002
|
Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv
2002
|
|
| 2002
|
Model prediction of treatment planning for dose-fractionated radioimmunotherapy..
Cancer.
94:1264-1269.
2002
|
|
| 2002
|
Quantitation of cytosine deaminase mRNA by real-time reverse transcription polymerase chain reaction: A sensitive method for assessing 5-fluorocytosine toxicity in Vitro.
Analytical Biochemistry.
301:189-199.
2002
|
|
| 2002
|
Rationales, evidence, and design considerations for fractionated radioimmunotherapy..
Cancer.
94:1332-1348.
2002
|
|
| 2002
|
Targeted radiotherapy with [(90)Y]-SMT 487 in mice bearing human nonsmall cell lung tumor xenografts induced to express human somatostatin receptor subtype 2 with an adenoviral vector..
Cancer.
94:1298-1305.
2002
|
|
| 2002
|
Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas.
Cancer Research.
62:773-780.
2002
|
|
| 2002
|
Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv
2002
|
|
| 2002
|
Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus in mice.
Radiology.
223:417-425.
2002
|
|
| 2001
|
Gene therapy for the treatment of cancer..
Cancer Biotherapy and Radiopharmaceuticals.
16:275-288.
2001
|
|
| 2001
|
Detection and measurement of in vitro gene transfer by gamma camera imaging
2001
|
|
| 2001
|
A noninvasive reporter system to image adenoviral-mediated gene transfer to ovarian cancer xenografts.
Gynecologic Oncology.
83:432-438.
2001
|
|
| 2001
|
An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression.
Molecular Therapy.
4:223-231.
2001
|
|
| 2001
|
Simultaneous evaluation of dual gene transfer to adherent cells by gamma-ray imaging.
Nuclear Medicine and Biology.
28:135-144.
2001
|
|
| 2001
|
Update: Gene therapy for the treatment of cancer.
Cancer Biotherapy and Radiopharmaceuticals.
16:275-288.
2001
|
|
| 2000
|
Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers..
Journal of Clinical Oncology.
18:47S-53S.
2000
|
|
| 2000
|
A robust summarize-regress procedure for tissue-specific pharmacokinetics.
Journal of Biopharmaceutical Statistics.
10:251-264.
2000
|
|
| 2000
|
Molecular modification of a recombinant anti-CD3ε-directed immunotoxin by inducing terminal cysteine bridging enhances anti-GVHD efficacy and reduces organ toxicity in a lethal murine model.
Blood.
96:1157-1165.
2000
|
|
| 2000
|
Noninvasive monitoring of gene transfer using a reporter receptor imaged with a high-affinity peptide radiolabeled with 99mTc or 188Re.
Journal of Nuclear Medicine.
41:887-895.
2000
|
|
| 2000
|
A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo.
Molecular Therapy.
2:562-578.
2000
|
|
| 2000
|
An adenovirus encoding proapoptotic Bax induces apoptosis and enhances the radiation effect in human ovarian cancer.
Molecular Therapy.
1:545-554.
2000
|
|
| 2000
|
Experimental radioimmunotherapy.
Seminars in Radiation Oncology.
10:156-167.
2000
|
|
| 2000
|
Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models
2000
|
|
| 2000
|
Gene transfer strategies for improving radiolabeled peptide imaging and therapy.
Quarterly Journal of Nuclear Medicine.
44:208-223.
2000
|
|
| 2000
|
Radiation to control gene expression
2000
|
|
| 2000
|
Selectivity of tag-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro.
Clinical Cancer Research.
6:4323-4333.
2000
|
|
| 1999
|
Paclitaxel derivatives for targeted therapy of cancer: Toward the development of smart taxanes.
Journal of Medicinal Chemistry.
42:4919-4924.
1999
|
|
| 1999
|
Mouse models for internal radiation dosimetry [4] (multiple letters).
Journal of Nuclear Medicine.
40:1969-1970.
1999
|
|
| 1999
|
Improved synthesis of the bifunctional chelating agent 1,4,7,10- tetraaza-N-(1-carboxy-3-(4-nitrophenyl)propyl)-N',N'',N'''-tris(acetic acid)cyclododecane (PA-DOTA).
Bioorganic and Medicinal Chemistry.
7:2313-2320.
1999
|
|
| 1999
|
Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts..
Clinical Cancer Research.
5:2994s-3000s.
1999
|
|
| 1999
|
Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model..
Clinical Cancer Research.
5:3153s-3159s.
1999
|
|
| 1999
|
Targeting strategies for cancer radiotherapy..
Clinical Cancer Research.
5:3048s-3055s.
1999
|
|
| 1999
|
Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer.
Current Opinion in Oncology.
11:187-190.
1999
|
|
| 1999
|
In vivo localization of [111In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector.
Clinical Cancer Research.
5:383-393.
1999
|
|
| 1999
|
Biodistribution Study of 188Re-Labeled Trisuccin-HuCC49 and Trisuccin-HuCC49ΔCH2 Conjugates in Athymic Nude Mice Bearing Intraperitoneal Colon Cancer Xenografts.
Clinical Cancer Research.
5.
1999
|
|
| 1999
|
Combined modality therapy of A431 human epidermoid cancer using anti- EGFR antibody C225 and radiation.
Cancer Biotherapy and Radiopharmaceuticals.
14:451-463.
1999
|
|
| 1999
|
Cytosine deaminase and herpes simplex virus thymidine kinase gene expression via adenoviral infection of human cholangiocarcinoma cells occurs in the presence of human bile.
Tumor Targeting.
4:29-36.
1999
|
|
| 1999
|
Further studies on the protein conjugation of hydroxamic acid bifunctional chelating agents: Group-specific conjugation at two different loci.
Bioconjugate Chemistry.
10:18-23.
1999
|
|
| 1999
|
Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectors.
Cancer Gene Therapy.
6:209-219.
1999
|
|
| 1998
|
Differential susceptibility of primary and established human glioma cells to adenovirus infection: Targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer.
Cancer Research.
58:5738-5748.
1998
|
|
| 1998
|
Comparison of biodistribution of 131I CC49 mAb in athymic nude mice bearing LS174T colon cancer xenografts following bolus injection or continuous infusion.
Tumor Targeting.
3:178-190.
1998
|
|
| 1998
|
Genetic induction of antigens and receptors as targets for cancer radiotherapy.
Tumor Targeting.
3:122-137.
1998
|
|
| 1998
|
Radiosensitization mediated by a transfected anti-ERBB-2 single-chain antibody in vitro and in vivo
1998
|
|
| 1998
|
A mouse bone marrow dosimetry model.
Journal of Nuclear Medicine.
39:1243-1247.
1998
|
|
| 1998
|
Enhanced in vivo gene delivery to human ovarian cancer xenografts utilizing a tropism-modified adenovirus vector.
Tumor Targeting.
3:25-31.
1998
|
|
| 1998
|
Combined Cytosine Deaminase Expression, 5-Fluorocytosine Exposure, and Radiotherapy Increases Cytotoxicity to Cholangiocarcinoma Cells.
Journal of Gastrointestinal Surgery.
2:283-291.
1998
|
|
| 1997
|
Experimental tumor targeting with radiolabeled ligands..
Cancer.
80:2371-2377.
1997
|
|
| 1997
|
Synthesis of bombesin analogues for radiolabeling with rhenium-188..
Cancer.
80:2354-2359.
1997
|
|
| 1997
|
Tumor localization of a radiolabeled bombesin analogue in mice bearing human ovarian tumors induced to express the gastrin-releasing peptide receptor by an adenoviral vector..
Cancer.
80:2419-2424.
1997
|
|
| 1997
|
Localization of idine-125-mIP-Des-Met14bmbesin (7-13)NH2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transfer.
Journal of Nuclear Medicine.
38:1221-1229.
1997
|
|
| 1997
|
Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo.
Cancer Research.
57:4325-4332.
1997
|
|
| 1997
|
Conjugation of unprotected trisuccin, N-[tris[2-[(N-hydroxyamino)carbonyl]ethyl]methyl]succinamic acid, to monoclonal antibody CC49 by an improved active ester protocol.
Bioconjugate Chemistry.
8:766-771.
1997
|
|
| 1997
|
Adenoviral-mediated delivery of gastrin-releasing peptide receptor results in specific tumor localization of a bombesin analogue in vivo.
Clinical Cancer Research.
3:1187-1194.
1997
|
|
| 1997
|
Synthesis and biodistribution of peptide based 99mTc/186Re- MAGIPG-D612 monoclonal antibody in nude mice bearing colon cancer xenografts.
Cancer Biotherapy and Radiopharmaceuticals.
12:55-62.
1997
|
|
| 1997
|
Synthesis, rhenium-188 labeling and biodistribution studies of a phenolic ester derivative of trisuccin.
Cancer Biotherapy and Radiopharmaceuticals.
12:375-384.
1997
|
|
| 1997
|
Use of a novel cross-linking method to modify adenovirus tropism
1997
|
|
| 1996
|
Approaches to enhance cancer radiotherapy employing gene transfer methods
1996
|
|
| 1996
|
Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene
1996
|
|
| 1996
|
A quantitative study of radionuclide characteristics for radioimmunotherapy from 3D reconstructions using serial autoradiography
1996
|
|
| 1996
|
Experimental radioimmunotherapy: biological effectiveness and comparison with external beam radiation.
1996
|
|
| 1996
|
Synthesis of a new class of isothiocyanatopeptide bifunctional chelating agents for coupling to monoclonal antibodies.
International journal of peptide and protein research.
48:79-86.
1996
|
|
| 1995
|
Experimental approaches to increase radiolabeled antibody localization in tumors.
Cancer Research.
55.
1995
|
|
| 1995
|
Experimental approaches to increase radiolabeled antibody localization in tumors..
Cancer Research.
55:5729s-5732s.
1995
|
|
| 1995
|
Fractionated radioimmumotherapy of human colon carcinoma xenografts with131I-labeled monoclonal antibody CC49.
Cancer Research.
55.
1995
|
|
| 1995
|
Reconciliation of tumor dose response to external beam radiotherapy versus radioimmunotherapy with 131iodine-labeled antibody for a colon cancer model.
Cancer Research.
55.
1995
|
|
| 1994
|
A peptide-based bifunctional chelating agent for 99mTc- and 186Re-labeling of monoclonal antibodies..
Cancer.
73:769-773.
1994
|
|
| 1994
|
Radioiodination of monoclonal antibodies D612 and 17-1A with 3-iodophenylisothiocyanate and their biodistribution in tumor-bearing nude mice..
Cancer.
73:808-815.
1994
|
|
| 1994
|
Sensitization of radiolabeled monoclonal antibody therapy using bromodeoxyuridine..
Cancer.
73:999-1005.
1994
|
|
| 1994
|
A peptide‐based bifunctional chelating agent for 99mtc‐ and 186re‐labeling of monoclonal antibodies.
Cancer.
73:769-773.
1994
|
|
| 1994
|
Radioiodination of monoclonal antibodies d612 and 17‐1a with 3‐lodophenylisothiocyanate and their biodistribution in tumor‐bearing nude mice.
Cancer.
73:808-815.
1994
|
|
| 1994
|
Sensitization of radiolabeled monoclonal antibody therapy using bromodeoxyuridine.
Cancer.
73:999-1005.
1994
|
|
| 1994
|
Three‐dimensional reconstruction of monoclonal antibody uptake in tumor and calculation of beta dose‐rate nonuniformity.
Cancer.
73:912-918.
1994
|
|
| 1993
|
Synthesis of N-[Tris[2-[[N-(benzyloxy)amino]carbonyl]ethyl]methyl]succinamic Acid, Trisuccin. Hydroxamic Acid Derivatives as a New Class of Bifunctional Chelating Agents.
Bioconjugate Chemistry.
4:194-198.
1993
|
|
| 1993
|
Comparison of 131I- and 90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts
1993
|
|
| 1993
|
Erratum:'Variations in 3-D dose distributions for 131Indium-labeled monoclonal antibody' (Antibody,Immunoconjugates, and Radiopharmaceuticals,(1992)5(4)).
Antibody, Immunoconjugates, and Radiopharmaceuticals.
6:96.
1993
|
|
| 1993
|
Introduction: Radiolabeled antibody tumor dosimetry.
Medical Physics.
20:499-501.
1993
|
|
| 1993
|
New azomycin acyclonucleoside. Synthesis and biodistribution of radiohalogenated analogues in tumor‐bearing mice
1993
|
|
| 1992
|
Development of 3-iodophenylisothiocyanate for radioiodination of monoclonal antibodies.
International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.
43:1387-1391.
1992
|
|
| 1992
|
Improved Delivery of Radiolabeled Anti-Bl Monoclonal Antibody to Raji Lymphoma Xenografts by Predosing with Unlabeled Anti-Bl Monoclonal Antibody.
Cancer Research.
52:637-642.
1992
|
|
| 1992
|
Therapy with Unlabeled and 131I-labeled Pan-B-Cell Monoclonal Antibodies in Nude Mice Bearing Raji Burkitt's Lymphoma Xenografts.
Cancer Research.
52:6476-6481.
1992
|
|
| 1992
|
Three-dimensional tumor dosimetry for radioimmunotherapy using serial autoradiography
1992
|
|
| 1991
|
Radiotherapy in Mice with Yttrium-90-labeled Anti-Ly1 Monoclonal Antibody: Therapy of Established Graft-versus-Host Disease Induced across the Major Histocompatibility Barrier.
Cancer Research.
51:1891-1897.
1991
|
|
| 1991
|
Radiotherapy in Mice with Yttrium-90-labeled Anti-Ly1 Monoclonal Antibody: Therapy of the T Cell Lymphoma EL4.
Cancer Research.
51:1883-1890.
1991
|
|
| 1991
|
18F‐2‐deoxy‐2‐fluoro‐D‐glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron‐emission tomography.
Cancer.
67:1544-1550.
1991
|
|
| 1991
|
A Sensitivity Study of Micro-TLDs for in Vivo Dosimetry of Radioimmunotherapy.
Medical Physics.
18:1195-1199.
1991
|
|
| 1991
|
Effect of backscatter on cell survival for a clinical electron beam.
Radiotherapy and Oncology.
21:269-272.
1991
|
|
| 1991
|
The expression of epidermal growth factor receptor on human bladder cancer: Potential use in radioimmunoscintigraphy
1991
|
|
| 1991
|
[125I]-IPM. Radioimmunoconjugator antibody radiolabeling reagent.
Drugs of the future.
16:1004-1007.
1991
|
|
| 1990
|
A new conjugating agent for radioiodination of proteins: Low in vivo deiodination of a radiolabeled antibody in a tumor model
1990
|
|
| 1990
|
A comparison of 131I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts
1990
|
|
| 1990
|
Comparison of antigen expression on normal urothelial cells in tissue section and tissue culture
1990
|
|
| 1990
|
New trends in the use of radioimmunoconjugates for the therapy of cancer..
Targeted diagnosis and therapy.
3:215-255.
1990
|
|
| 1989
|
Radioiodinated iodophenyl maleimide: A potential radioimmunoconjugate with low in vivo deiodination.
NUC Compact.
20:145-149.
1989
|
|
| 1989
|
The role of ricin B chain in the intracellular trafficking of anti-CD5 immunotoxins.
Journal of Immunology.
142:1755-1766.
1989
|
|
| 1988
|
Cytotoxic effects of anti-cd5 radioimmunotoxins on human tumors in vitro and in a nude mouse model.
Cancer Research.
48:7107-7114.
1988
|
|
| 1988
|
Localization and Imaging of Radiolabeled Monoclonal Antibodies Against Colorectal Carcinoma in Tumor-Bearing Nude Mice.
Cancer Research.
48:4256-4260.
1988
|
|
| 1988
|
Localization and Imaging with Radioiodine-labeled Monoclonal Antibodies in a Xenogeneic Tumor Model for Human B-Cell Lymphoma.
Cancer Research.
48:2475-2482.
1988
|
|
| 1988
|
Localization and imaging of radiolabeled monoclonal antibodies against colorectal carcinoma in tumor-bearing nude mice.
Cancer Research.
48:4324-4333.
1988
|
|
| 1987
|
Human leukemia cell binding and killing by anti-CD5 radioimmunotoxins
1987
|
|
| 1986
|
Antigenic modulation by anti-CD5 immunotoxins.
Journal of Immunology.
136:4721-4728.
1986
|
|
| 1985
|
Comparison of the distribution and binding of monoclonal antibodies labeled with 131-iodine or 111-indium
1985
|
|
| 1985
|
Radiolabeling of monoclonal antibody against carcinoembryonic antigen with 88Y and biodistribution studies.
International journal of nuclear medicine and biology.
12:79-82.
1985
|
|
| 1985
|
Radiolabeling of monoclonal antibody against carcinoembryonic antigen with 88Y and biodistribution studies.
International journal of nuclear medicine and biology.
12:79-82.
1985
|
|
| 1982
|
Localization of Radiolabeled Antibody in SVT2 Tumor Increases with Immunosuppression of the Host
1982
|
|
| 1980
|
Localization of radiolabeled mouse alloantibody in a sarcoma induced by 3-methylcholanthrene.
Journal of Nuclear Medicine.
21:77-80.
1980
|
|
| 1979
|
Distribution of radiolabled alloantibodies in mice bearing 3-methylcholanthrene-induced sarcomas.
Cancer Research.
39:3363-3368.
1979
|
|
| 1974
|
Preferential in vivo localization of 125I-labeled antibody in a carcinogen-induced syngeneic rat tumor..
Progress in Experimental Tumor Research.
19:270-283.
1974
|
|
| 1972
|
Effect of Rat Tumor Allografts on the Blood Level of Passively Transferred Alloantibodies
1972
|
|
| 1972
|
Localization of an 125I-Labeled Rat Transplantation Antibody in Tumors Carrying the Corresponding Antigen
1972
|
|
